AbbVie Raises Outlook Amid Parkinson's Asset Acquisitions

AbbVie reported Q2 2025 sales of $15.42 bln, beating consensus, with a 6.6% YoY increase. Immunology portfolio sales rose 9.5% to $7.63 bln, while oncology portfolio sales increased 2.6% to $1.68 bln. Neuroscience portfolio sales surged 24.2% to $2.68 bln. AbbVie raised its FY25 adjusted earnings outlook to $11.88-$12.08 per share, citing proactive inventory management and a regulatory exemption for its cancer therapy drug Venclexta under the One Big Beautiful Bill Act.

AbbVie Inc. (NYSE: ABBV) reported its second-quarter 2025 financial results, showcasing a 6.6% year-over-year (YoY) increase in net revenues to $15.423 billion, surpassing the consensus estimate of $15.03 billion [1]. The company's immunology portfolio, which includes drugs like Skyrizi and Rinvoq, drove significant growth, with revenues reaching $7.631 billion, a 9.5% increase YoY [2]. The oncology portfolio also performed well, with sales increasing 2.6% to $1.68 billion, while the neuroscience portfolio surged 24.2% to $2.68 billion [3].

AbbVie's adjusted diluted earnings per share (EPS) rose 12.1% to $2.97, but GAAP EPS declined 32.5% to $0.52 due to acquisition-related expenses and in-process research and development costs [1]. Despite this, the company raised its full-year 2025 adjusted EPS guidance to $11.88-$12.08 per share, citing strong global uptake of newer products and recent regulatory approvals [1].

Key highlights from the quarter include FDA approval for Rinvoq in giant cell arteritis and Emrelis for non-small cell lung cancer. Additionally, the company's proactive inventory management and a regulatory exemption for its cancer therapy drug Venclexta under the One Big Beautiful Bill Act are expected to support future growth [2].

Looking ahead, AbbVie appears well-positioned to navigate further declines in Humira sales as its immunology and neuroscience products gain traction globally. The updated 2025 outlook points to stable earnings growth, contingent on continued pipeline progression and successful commercialization of new treatments [1].

References:
[1] https://mlq.ai/news/abbvie-beats-q2-revenue-estimates-raises-2025-earnings-outlook-amid-strong-immunology-performance/
[2] https://www.benzinga.com/markets/earnings/25/07/46762357/abbvie-lifts-outlook-eyes-parkinsons-assets-as-next-growth-frontier
[3] https://www.stocktitan.net/news/ABBV/abb-vie-reports-second-quarter-2025-financial-lg1r18h0ozjq.html